rs5030827
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_000551.4(VHL):c.250G>A(p.Val84Met) variant causes a missense change. The variant allele was found at a frequency of 0.000000689 in 1,451,712 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V84A) has been classified as Uncertain significance.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.250G>A | p.Val84Met | missense_variant | 1/3 | ENST00000256474.3 | |
VHL | NM_001354723.2 | c.250G>A | p.Val84Met | missense_variant | 1/3 | ||
VHL | NM_198156.3 | c.250G>A | p.Val84Met | missense_variant | 1/2 | ||
VHL | NR_176335.1 | n.320G>A | non_coding_transcript_exon_variant | 1/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
VHL | ENST00000256474.3 | c.250G>A | p.Val84Met | missense_variant | 1/3 | 1 | NM_000551.4 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 33
GnomAD3 exomes AF: 0.00000438 AC: 1AN: 228506Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 126898
GnomAD4 exome AF: 6.89e-7 AC: 1AN: 1451712Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 722542
GnomAD4 genome ? Cov.: 33
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Aug 01, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Oct 20, 2021 | - - |
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 17, 2023 | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 84 of the VHL protein (p.Val84Met). This variant is present in population databases (no rsID available, gnomAD 0.001%). This missense change has been observed in individuals with clinical features of von Hippel-Lindau syndrome (PMID: 17688370; external communication). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 428813). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on VHL function (PMID: 17906660). This variant disrupts the p.Val84 amino acid residue in VHL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8592333, 11331612, 16502427, 25078357). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 16, 2022 | The p.V84M variant (also known as c.250G>A), located in coding exon 1 of the VHL gene, results from a G to A substitution at nucleotide position 250. The valine at codon 84 is replaced by methionine, an amino acid with highly similar properties. This alteration has been reported in an individual affected with bilateral pheochromocytoma diagnosed at ages 1 year and 4 years; of note, this individual's father was also diagnosed with pheochromocytoma at age 40; however, genetic testing was not performed on the father (Stanojevic BR et al. Neoplasma. 2007;54:402-6). It was also identified in a patient diagnosed with a pheochromocytoma at age 8, with recurrence of disease at age 26 (Eisenhofer G et al. Horm. Metab. Res. 2012 May;44(5):343-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at